FIRST AMENDMENT TO EXCLUSIVE LICENSE AND CO-FUNDING AGREEMENT-Funding Agreement • May 10th, 2022 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This First Amendment (this “First Amendment”), entered into as of March 15, 2022 but effective retroactively as of October 7, 2020 (the “First Amendment Effective Date”), is made to that certain Exclusive License and Co-Funding Agreement (the “Agreement”), dated as of October 7, 2020, by and between Takeda Pharmaceuticals U.S.A., Inc., a company incorporated under the laws of the State of Delaware (“Takeda”), and Arrowhead Pharmaceuticals Inc., a company organized and existing under the Laws of the State of Delaware (“Arrowhead”). The parties to this Agreement are collectively referred to as the “Parties” and individually as a “Party.” Capitalized terms used but not defined in this First Amendment have the meanings ascribed to them in the Agreement.
